Please login to the form below

Not currently logged in
Email:
Password:

Sanofi wins Eloxatin patent case

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin until August 2012 following a patent challenge from Sun Pharmaceuticals

A US district court has ruled in favour of Sanofi retaining marketing exclusivity for colorectal cancer treatment Eloxatin (oxaliplatin) until August 2012 following a patent challenge from Sun Pharmaceuticals.

Sun Pharma was appealing a district court ruling from April 2010 requiring Sun to cease selling its generic oxaliplatin products as of June 30, 2010.

Sanofi had previously reached settlement agreements with several other pharmaceutical companies, including Teva Pharmaceutical and Sandoz, prohibiting the sale of generic Eloxatin products in the US until August, 2012.

In recently released financial results, Sanofi reported the drug had sales €436m for Sanofi during the first half of 2011.

The company said it still sees Eloxatin as an important therapeutic option for healthcare professionals treating patients with colorectal cancer.

19th September 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics